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An in silico structural 
approach to critical quality 
attributes assessment of 
biopharmaceutical products
AIMS
▪ Structural data collection about overall IgG1 
▪ Identification of suitable templates
▪ Homology modeling of both IgG1 k and l and structural analysis of whole 
mAbs
▪ Identification of differences between k and l chains by bioinformatics tools
CONCLUSIONS
▪ A chimeric approach is the most suitable to build homology models of 
mAbs, for both l and k light chains
▪ Ser216 of l chains can induce slight differences in IgG1l, expecially 
on the hinge region
▪ This structural difference could be responsible for different physical-
chemical properties between IgG1 subtypes
▪ The structural approach proposed can be useful in CQA identification 
and assessment 
Immune-cell responses 
by the interaction with 
specific receptors
Antigen recognition and binding
IgG1: STRUCTURAL INSIGHTS
IgG1s are the most expressed immunoglobulin sub-class in humans. They have a “Y-shaped” conformation,
due their structural organization: two heterodimers of heavy and light chains (HC and LC), linked each other
by interchain disulphide bonds, assembly to form a Y-architecture.
At the Fab level, the three hypervariability regions, called CDRs
(Complementarity Determining Regions), drive the antigen
recognition. They differ in sequence and in length among different
antibodies, causing the specificity and affinity for the target2.
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Currently, monoclonal antibodies (mAbs) are one of the most innovative class of
biopharmaceuticals in development, due their ability to specifically recognize
molecular targets.
Pharmaceutical companies have implemented a new strategy to control the
quality profile of mAbs during the development phase: the “Quality by Design”
(Qbd) approach. QbD is essentially focused on critical quality attributes (CQAs)
assessment. CQAs are defined as all the physical, chemical, biological or
microbiological properties that should be within an appropriate limit, range, or
distribution to ensure the desired product quality1. These attributes have an
impact on bioactivity, PK, immunogenicity and safety and are generally
associated with the drug substance, excipients, intermediates and
pharmaceutical product. In this global approach, the introduction of a structural
investigation, can be very useful to early identify and assess potential CQAs
(pCQAs) and for drug substance and excipients understanding.
BACKGROUND
Due to the lack of experimental data on complete IgG1s structures, we developed an in silico strategy to predict the full structure of this antibodies class. We focused our study on the two
subtypes of light chain, l and k, due their different physical-chemical properties3,4 and the impact of this feature on molecules bioactivity. Usually, for therapeutic mAbs, only the X-ray structure of
Fab portions is solved. So, we used a homology modeling chimeric approach to obtain a prediction of whole 3D structure of proteins by a combination of different templates.
In detail, we investigated the atomistic structure of two therapeutic and commercially available mAbs: avelumab, a recently approved anti-PDL1 IgG1l, indicated for Merkell-cell carcinoma5, and
adalimumab, an anti-TNFa IgG1k used in the treatment of rheumatoid and psoriatic arthritis and for the Crohn disease6. We decided to use as template to model the Fab portion 4NKI.pdb7 and
4NYL.pdb, respectively, the X-ray structures of avelumab and adalimumab Fab. Then, we used 1HZH.pdb8, the only one human fully crystalized IgG1, as Fc and backbone template for both mAbs.
All the computational procedures were carried out by MOE software9.
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IgG1k vs IgG1l
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The structural superposition of two models shows
differences at CDRs, due to sequence heterogeneity,
and a quite different orientation, mainly concentrated
at the Fab C-terminal, close to hinge region. This
feature may be influenced by the residue Ser216
displayed only in the lLC of avelumab (in green) and
absent in adalimumab (in grey).
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Please note that avelumab has been approved in various countries for the treatment of metastatic 
Merkel cell carcinoma and in the US for treatment of advanced urothelial carcinoma progressed after 
platinum-containing treatment.
